Mabwell Bioscience Receives NMPA Approval for 9MW2821 Clinical Trials
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it...
WuXi Biologics Expands Sterile Filling Capabilities in Germany with New Line
China’s Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced plans...
Jiangxi Jemincare’s JMX-2002 Liposome Injection Gets NMPA Clinical Clearance
Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced that it has received clinical clearance...
Lion TCR Gains NMPA Approval for mRNA TCR-T Therapy GZL-016 in HCC
Singapore-based clinical-stage biotechnology company Lion TCR, supported by Chinese investors, has secured tacit clinical approval...
BeiGene to Rebrand as BeOne Medicines, Emphasizing Global Commitment to Cancer Care
BeiGene Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading global innovator in oncology treatments,...
Eli Lilly’s Tirzepatide Shows Sustained Weight Loss in 176-Week Study
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has released 176-week follow-up data from...
GE Healthcare’s SIGNA MAGNUS MRI Scanner Receives FDA 510(k) Clearance
US medical device and life sciences leader GE Healthcare Technologies Inc. (NASDAQ: GEHC) has announced...
Cullgen and Pulmatrix Merge to Form Nasdaq-Listed Protein Degradation Company
Cullgen Inc., a clinical-stage biopharmaceutical company with operations in China, the US, and Japan, is...
ImmuneOnco Initiates Phase II Study for IMM27M in ER+ Advanced Breast Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a leading biopharmaceutical company specializing in immuno-oncology, has...
Huadong Medicine’s Biosimilar SaiLeXin Receives First National Prescription in China
China-based pharmaceutical company Huadong Medicine Co., Ltd (SHE: 000963) has announced a significant milestone with...
Zucara Therapeutics Secures $20M Series B Financing Led by Sanofi and PXV Fund
Canada-based diabetes life sciences company, Zucara Therapeutics Inc., has announced the receipt of a strategic...
Novartis’ Pluvicto Accepted for Review by China’s NMPA for Prostate Cancer Treatment
The Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) has accepted...
Daiichi Sankyo and AstraZeneca File BLA for Datopotamab Deruxtecan in NSCLC
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN), partners in the development of innovative...
Zhejiang Dian Diagnostics Partners with SNN/CRHA for Optic Nerve Disease Research
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostic solutions provider, has formed...
BioNTech Seals Acquisition of China’s Biotheus for Up to $950M
China’s Biotheus Inc. has entered into a definitive acquisition agreement with Germany-based BioNTech SE (NASDAQ:...
Arctic Vision and Santen Ink Deal for ARVN001 Commercialization in China
China-based ophthalmology specialist, Arctic Vision, has entered into a strategic collaboration with Japan’s Santen Pharmaceutical...
Pfizer Considers Sale of Hospital Unit Amid Pressure from Starboard Value
Pfizer Inc. (NYSE: PFE) is reportedly considering the sale of its hospital unit, Pfizer Hospital,...
FibroGen Inc. Reports 15% YOY Revenue Growth in Q3 2024 Led by Evrenzo
US-based biopharmaceutical company FibroGen Inc. (NASDAQ: FGEN) has released its Q3 2024 financial report, showing...
AstraZeneca Inc. Reports 21% YOY Revenue Growth in Q3 2024 Financials
UK-based pharmaceutical giant AstraZeneca Inc. (AZ, NASDAQ: AZN) has reported its financial performance for the...
BeiGene’s Q3 2024 Results Show 28% YOY Revenue Growth Driven by Brukinsa and Tevimbra
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a China-based biotech company, has released its...